MA27925A1 - Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur - Google Patents
Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeurInfo
- Publication number
- MA27925A1 MA27925A1 MA28737A MA28737A MA27925A1 MA 27925 A1 MA27925 A1 MA 27925A1 MA 28737 A MA28737 A MA 28737A MA 28737 A MA28737 A MA 28737A MA 27925 A1 MA27925 A1 MA 27925A1
- Authority
- MA
- Morocco
- Prior art keywords
- tumor
- cathepsin
- treatment
- bone loss
- bisphophonate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMBINAISONS D'UN INHIBITEUR DE CATHEPSINE K ET D'UN BISPHOSPHONATE DANS LE TRAITEMENT D'UNE METASTASE OSSEUSE, D'UN DEVELOPPEMENT DE CELLULES CANCEREUSES ET D'UNE PERTE OSSEUSE INDUITE PAR UNE TUMEUR" La présente invention concerne des préparations pharmaceutiques comprenant certains types de bisphosphonates et certains types d'inhibiteurs de cathepsine K, en particulier dans la prévention et le traitement de métastases osseuses, d'une hypercalcémie induite par une tumeur, d'un développement de tumeur, d'une perte osseuse induite par une tumeur et de maladies se manifestant par une perte osseuse telles que l'ostéoporose ou une perte osseuse induite par une thérapie anti-cancéreuse.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48892503P | 2003-07-21 | 2003-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27925A1 true MA27925A1 (fr) | 2006-06-01 |
Family
ID=34135094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28737A MA27925A1 (fr) | 2003-07-21 | 2006-01-18 | Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur |
Country Status (21)
Country | Link |
---|---|
US (1) | US20060281714A1 (fr) |
EP (1) | EP1651238A1 (fr) |
JP (1) | JP2006528151A (fr) |
KR (1) | KR20060037382A (fr) |
CN (1) | CN100406016C (fr) |
AR (1) | AR045728A1 (fr) |
AU (1) | AU2004262903B2 (fr) |
BR (1) | BRPI0412769A (fr) |
CA (1) | CA2532948A1 (fr) |
CO (1) | CO5680441A2 (fr) |
EC (1) | ECSP066293A (fr) |
IL (1) | IL172913A0 (fr) |
IS (1) | IS8311A (fr) |
MA (1) | MA27925A1 (fr) |
MX (1) | MXPA06000790A (fr) |
NO (1) | NO20060851L (fr) |
PE (1) | PE20050328A1 (fr) |
RU (1) | RU2006105100A (fr) |
TN (1) | TNSN06021A1 (fr) |
TW (1) | TW200510436A (fr) |
WO (1) | WO2005014006A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070135448A1 (en) * | 2003-11-19 | 2007-06-14 | Martin Missbach | Use of cathepsin k inhibitors for treating of severe bone loss diseases |
GB0427380D0 (en) * | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
WO2007038397A2 (fr) * | 2005-09-26 | 2007-04-05 | Novartis Ag | Marqueurs moleculaires associes a la metastase osseuse |
US20100331545A1 (en) * | 2007-10-24 | 2010-12-30 | Nippon Chemiphar Co., Ltd. | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
EP3426674A4 (fr) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | Composés céto-amides cycliques utilisés en tant que modulateurs de la calpaïne, et leurs procédés de production et d'utilisation |
AU2017292646A1 (en) | 2016-07-05 | 2019-02-07 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
PE20191153A1 (es) | 2016-09-28 | 2019-09-05 | Blade Therapeutics Inc | Moduladores de calpainas y usos terapeuticos de los mismos |
WO2020002565A1 (fr) | 2018-06-27 | 2020-01-02 | Sabine Bauer | Implants pour recruter et retirer des cellules tumorales circulantes |
WO2021122803A2 (fr) | 2019-12-17 | 2021-06-24 | Cirlo Gmbh | Ensembles dispositifs de cathéter allongés de forme tubulaire destinés à entrer en interaction avec des composants de fluides corporels, procédé de récupération de cellules, d'agrégats de cellules et d'exosomes à partir d'un dispositif de cathéter allongé de forme tubulaire et ensembles dispositifs de cathéter allongés de forme tubulaire intelligents pour surveiller l'interaction avec des composants de fluides corporels |
WO2023212104A1 (fr) * | 2022-04-27 | 2023-11-02 | The Regents Of The University Of California | Méthodes et agents pour prévenir le vieillissement squelettique, l'ostéoporose et l'obésité |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5501969A (en) * | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
US6544767B1 (en) * | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US5998390A (en) * | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
AU779177B2 (en) * | 1999-03-15 | 2005-01-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
IL146520A0 (en) * | 1999-05-21 | 2002-07-25 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
DE60225316T2 (de) * | 2001-11-13 | 2009-02-26 | AXYS Pharmaceuticals, Inc., South San Francisco | Cyanoalkylamino-derivate als protease-hemmer |
-
2004
- 2004-07-20 MX MXPA06000790A patent/MXPA06000790A/es not_active Application Discontinuation
- 2004-07-20 EP EP04741174A patent/EP1651238A1/fr not_active Withdrawn
- 2004-07-20 PE PE2004000692A patent/PE20050328A1/es not_active Application Discontinuation
- 2004-07-20 AU AU2004262903A patent/AU2004262903B2/en not_active Ceased
- 2004-07-20 KR KR1020067001370A patent/KR20060037382A/ko not_active Application Discontinuation
- 2004-07-20 BR BRPI0412769-2A patent/BRPI0412769A/pt not_active IP Right Cessation
- 2004-07-20 WO PCT/EP2004/008107 patent/WO2005014006A1/fr active Application Filing
- 2004-07-20 AR ARP040102560A patent/AR045728A1/es not_active Application Discontinuation
- 2004-07-20 RU RU2006105100/04A patent/RU2006105100A/ru not_active Application Discontinuation
- 2004-07-20 CA CA002532948A patent/CA2532948A1/fr not_active Abandoned
- 2004-07-20 US US10/565,453 patent/US20060281714A1/en not_active Abandoned
- 2004-07-20 JP JP2006520778A patent/JP2006528151A/ja active Pending
- 2004-07-20 CN CNB2004800211100A patent/CN100406016C/zh not_active Expired - Fee Related
- 2004-07-20 TW TW093121646A patent/TW200510436A/zh unknown
-
2005
- 2005-12-29 IL IL172913A patent/IL172913A0/en unknown
-
2006
- 2006-01-18 MA MA28737A patent/MA27925A1/fr unknown
- 2006-01-19 EC EC2006006293A patent/ECSP066293A/es unknown
- 2006-01-20 TN TNP2006000021A patent/TNSN06021A1/en unknown
- 2006-02-17 IS IS8311A patent/IS8311A/is unknown
- 2006-02-21 NO NO20060851A patent/NO20060851L/no not_active Application Discontinuation
- 2006-02-21 CO CO06016980A patent/CO5680441A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200510436A (en) | 2005-03-16 |
JP2006528151A (ja) | 2006-12-14 |
CO5680441A2 (es) | 2006-09-29 |
RU2006105100A (ru) | 2007-09-20 |
IL172913A0 (en) | 2006-06-11 |
US20060281714A1 (en) | 2006-12-14 |
IS8311A (is) | 2006-02-17 |
TNSN06021A1 (en) | 2007-10-03 |
AR045728A1 (es) | 2005-11-09 |
CA2532948A1 (fr) | 2005-02-17 |
KR20060037382A (ko) | 2006-05-03 |
PE20050328A1 (es) | 2005-06-16 |
CN1826124A (zh) | 2006-08-30 |
AU2004262903B2 (en) | 2007-08-23 |
ECSP066293A (es) | 2006-07-28 |
MXPA06000790A (es) | 2006-04-07 |
WO2005014006A1 (fr) | 2005-02-17 |
BRPI0412769A (pt) | 2006-09-26 |
CN100406016C (zh) | 2008-07-30 |
AU2004262903A1 (en) | 2005-02-17 |
NO20060851L (no) | 2006-04-21 |
EP1651238A1 (fr) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27925A1 (fr) | Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur | |
SE9901272D0 (sv) | New improved formulation | |
TR199800767T2 (xx) | Proteaz engelleyicileri. | |
BRPI0418096A (pt) | formulações farmacêuticas de bisfosfonatos | |
TR200101103T2 (tr) | CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar | |
NZ527157A (en) | Compositions for delivering bisphosphonates | |
MA28102A1 (fr) | Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus | |
BR0111210A (pt) | Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias | |
MEP90508A (en) | New pharmaceutical composition | |
BR0209365A (pt) | Usos farmacêuticos de bisfosfonatos | |
MY144318A (en) | Methods of treating hiv infection. | |
ATE232874T1 (de) | Prostaglandin-konjugate zur behandlung von knochenkrankheiten | |
HRP20080612T3 (en) | Combination of tenofovir, ritonavir and tmc114 | |
AU5029599A (en) | Methods for eradication of nanobacteria | |
CY1109596T1 (el) | Αναστολεις φωσφατασων cdc25 | |
TR199902703T2 (xx) | Proteaz inhibit�rleri. | |
BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
BR0110913A (pt) | Método de administrar um bisfosfonato | |
BR0309757A (pt) | 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases | |
HUP0202969A2 (hu) | Sztatinok alkalmazása csontlebontó sejtek képződésének gátlására és ezeket tartalmazó gyógyszerkészítmények | |
PT1814879E (pt) | Derivados de 4,7-dioxobenzotiazole-2-carboxamidas, sua preparação e suas aplicações terapêuticas | |
HUP0204097A2 (hu) | Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására | |
HUP0402061A2 (hu) | Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények | |
BR0307021A (pt) | Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários | |
FR2852847B1 (fr) | Composition renfermant une superoxyde dismutase et un inhibiteur de la 5-lipoxygenase selectionne et applications |